Clinical Trial Update: Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating grazoprevir, elbasvir, and sofosbuvir for chronic hepatitis C infection showing efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2016-11-17